跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 47 条关于
“Mizuho”
全部
47
临床试验
2
药物
3
机构
5
资讯
37
去年
Apellis Faces Setback as EMA Rejects Pegcetacoplan, Mizuho Lowers Price Target
2年前
Apellis Awaits EU Decision on Pegcetacoplan (Syfovre) Amidst Positive Phase 3 Kidney Data
去年
Mizuho Securities Maintains Hold Rating on Neurocrine as Osavampator Development Faces Timeline Uncertainties
3个月前
Mizuho Strategist Reframes Healthcare as a Value Sector Amid Pharma Underperformance, Highlights Merck's Keytruda Dominance
去年
Sarepta Therapeutics Receives Buy Rating Due to Strong Elevidys Launch and Promising Pipeline
去年
Insmed's TPIP and Brensocatib Programs Show Promise in Rare Pulmonary Diseases
去年
AbbVie's Schizophrenia Drug Emraclidine Fails in Phase 2 Trials, Impacting Cerevel Acquisition
去年
Vigil Neuroscience Reports Promising Early-Stage Data for Novel Alzheimer's Drug
去年
Ziftomenib Achieves Primary Endpoint in Pivotal AML Trial, Kura and Kyowa Kirin Prepare FDA Filing
去年
Vertex's Non-Opioid Pain Drug Suzetrigine Awaits Key Study Results and FDA Decision
第 1 页,共 4 页
上一页
下一页